Pharmaceutical manufacturers of Ezetimibe

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Headquartered in Mumbai, India, Lupin is a global pharmaceutical leader with a footprint across the U.S., LATAM, APAC, EMEA and India, with products distributed in over 100 markets. With a diverse portfolio of over 1,200 products, Lupin remains committed to its mission of making quality healthcare accessible to the communities we serve. Our visionary Founder, Dr. Desh Bandhu Gupta, instilled in us the importance of offering quality, affordable and innovative medicines and being a responsible corporate citizen, making a positive difference to patients, communities and the environment.

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA. The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible.

Glenmark Pharmaceuticals Limited is a global pharmaceutical company based in Mumbai, India. The company focuses on developing and manufacturing generic and innovative drugs. Their therapeutic areas of expertise include dermatology, respiratory, and oncology. They also manufacture high-quality affordable generic products for the US and European markets through Glenmark Life Sciences, an independent unit of Glenmark Pharmaceuticals.

We are a technology-focused, multi-dimensional pharmaceutical company having state-of-the-art manufacturing capabilities in diverse therapeutic areas such as Cardiology, Diabetology, Pain Management, Dermatology, Ophthalmology, Neurology and more. We strive towards unlocking the power of science to provide access to affordable and innovative medicines to improve health outcomes and make a difference in people's lives across the globe. As we continue to champion the cause of Make-in-India through our steady expansion across various Indian states, we create job opportunities and drive social responsibility programs in education, healthcare, rural development and environmental protection to add value to our local communities. Our roadmap is to continue investing in discovering, developing, manufacturing, and commercializing innovative medicines. Meeting the growth and profitability goals through successful innovation in digital healthcare trends and commercial excellence will continue to be the driving factors over the next decade.

Our objective is to pave the path to a more wholesome future. However, we are also concerned about the manner in which we collectively achieve this goal. Being a company whose products impact the well-being of individuals worldwide, we uphold ourselves to a stringent standard and anticipate others to treat us likewise. We are advocates of transparent, truthful, and principled operation with the utmost level of ethics and honesty. This encompasses ensuring the company's compliance with all relevant laws and regulations on a global scale.

Established in 1984, Neuland Laboratories Limited is a publicly traded company based in Hyderabad, India. The organization offers solutions throughout the entire range of the pharmaceutical industry's chemical needs, from synthesizing library compounds to providing NCEs and advanced intermediates at different stages in the clinical life cycle, as well as for commercial launch. Neuland's specialty lies in the production of APIs and advanced intermediates from its facilities approved by the USFDA. Its primary expertise is the application of effective process chemistry to manufacturing in a compliant regulatory setting.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Situated in Hyderabad, India, Symed Labs Ltd is a prominent and innovative producer of Active Pharmaceutical Ingredients (APIs) & a comprehensive solution provider for the pharmaceutical sector for chemistry related services. Symed labs has autonomously created processes for more than fifty APIs across various therapeutic categories in the laboratory and upscaled them to plant, as well as vending them to over 600 clients in 30 nations in the regulated and less regulated markets

Established in 1973 and based in Mumbai, India, Alkem started its operations as a healthcare marketing firm. Alkem is a major participant in the market for branded and generic drugs in India. The company has a strong presence in various therapeutic segments such as Anti-infective, Gastro-intestinal, Pain Management, Vitamins/Minerals/Nutritions, Central Nervous System, Anti-diabetic, Anti-osteoporosis, Anti-malarial, Cardiovascular, Immunosuppressants, and Nutraceutical segment.

Indoco Remedies Limited, based in India, is an emerging, fully integrated, research-oriented pharmaceutical firm with a global presence. We manufacture a diverse range of cost-effective, high-quality products in various therapeutic sectors that are widely embraced by healthcare professionals and clients across the globe. The company boasts a robust production infrastructure, a focus on Research & Development, and is uniquely positioned as a preferred collaborator providing comprehensive solutions to pharmaceutical companies marketing generics

Headquartered in Chandigarh, India, Ind-Swift Laboratories Ltd. today is a global manufacturer of APIs, Intermediates, and formulations (through group collaboration). With regulated 6+ manufacturing sites (including 2 group subsidiaries) in Punjab and Jammu, we cater to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. Today, Ind-Swift Laboratories Ltd. is a significant player in manufacturing APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. We also hold global leadership positions in the Macrolide Antibiotic segment.

Glenmark Life Sciences Limited is a prominent producer and developer of specialized, high-value, non-generic, active pharmaceutical ingredients (APIs) within chronic therapeutic fields such as heart disease, disorders of the central nervous system, pain management, and diabetes. The corporation is progressively offering CDMO services to various multinational and specialized pharmaceutical firms. It maintains a varied collection of over 137 compounds and delivers its merchandise to clients in India, Europe, North America, Latin America, Japan, and other parts of the globe (ROW).

Viyash embodies integrity and guidance in all aspects. As a fully-integrated pharmaceutical firm, we possess a robust collection of unique formulations, APIs, and advanced intermediates. Viyash and its affiliated companies manage 10 API/Intermediate facilities, boasting a combined capacity of approximately 2000 KL and diverse capabilities across various categories - small/large volume, potent/non-potent, regulated/semi-regulated markets. Additionally, we oversee a formulation manufacturing facility in New Jersey, USA, with a capacity of around 1.2 billion units.

We at Raks are dedicated to develop and manufacture active pharmaceutical ingredients and intermediates. We are committed to create value through intellectual property, quality systems and customer relation across the globe. We are research driven company providing cost effective and environmental friendly technologies with safety and quality as primary focus.

We have more than 20 years of experience providing a range of contract research, development and manufacturing services across the drug development continuum, with a focus on early-stage discovery and development of new molecular entities (NMEs). Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement.

Lunan Pharma is a prominent pharmaceutical firm dedicated to enhancing human well-being through the production and promotion of top-quality pharmaceutical products. The company achieved total sales revenues of 1.8 billion dollars in 2020 and is ranked among the top 22 in China.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Tianyu Pharmaceutical, Co., Ltd was established in 1993. It is engaged in the research, development and manufacturing of APIs and advanced intermediates with a registered capitalization of RMB120 million. The company comprises 6 wholly-owned subsidiaries with a total employee population in excess of 2600 and occupying an area of over 470,000 ㎡. Tianyu is recognized as a model high-tech enterprise in Chinas Torch Program. Tianyu is specializing in pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant and anti-asthmatic series. The products are well sold to domestic and overseas markets, winning customer`s recognition and praise.

Hanmi has experienced notable expansion since its establishment in 1973 and has emerged as the most prominent company among pharmaceutical firms in South Korea. We take pride in being recognized as a global frontrunner in the production of high-quality API for cephalosporins, cardiovascular, anti-diabetic, gastrointestinal, and CNS medications. The facilities have undergone inspection and received approval from UK MHRA, German BSG, Australian TGA, and US FDA. Hanmi has successfully developed and introduced new combination drugs and a series of IMDs using its patented process